Selected Grants
Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy the Safety of Vamifeport (CSL624) in Adults with HFE-related Hereditary Hemochromatosis (FERROCLEAR)
Clinical TrialPrincipal Investigator · Awarded by CSL Behring LLC · 2026 - 2030The spectrum of cognitive impairment including Alzheimer's Disease and Related Dementias after liver transplantation: from the Multi-Center Functional Assessment in Liver Transplantation (FrAILT) Study
ResearchPrincipal Investigator · Awarded by University of California - San Francisco · 2018 - 2028Investigating the role of frailty on outcomes in acutely ill patients with cirrhosis undergoing liver transplantation in the acute care setting
ResearchPrincipal Investigator · Awarded by University of California - San Francisco · 2023 - 2028CMV Vaccine in Orthotopic Liver Transplant Candidates (COLT) Study (Fixed Price)
Clinical TrialPrincipal Investigator · Awarded by University of California - San Francisco · 2024 - 2027CMV Vaccine in Orthotopic Liver Transplant Candidates (COLT) Study (Cost Reimbursable)
Clinical TrialPrincipal Investigator · Awarded by University of California - San Francisco · 2024 - 2027Prediction and Prevention of Hepatic Decompensation in Patients with Cirrhosis
Clinical TrialCo Investigator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2021 - 2026Utility of Biomarkers of Rejection and Kidney Injury in Tailoring Liver Transplant Immunosuppression (Fixed Price)
Clinical TrialPrincipal Investigator · Awarded by Northwestern University · 2021 - 2026P2b Primary Biliary Cholangitis trial CNP-104-CL-202
Clinical TrialPrincipal Investigator · Awarded by COUR Pharmaceuticals Development Company · 2025 - 2026A randomized open-label trial of deprescribing proton pump inhibitors to reduce the risk of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation
ResearchCollaborating Investigator · Awarded by SIR Foundation · 2022 - 2025Zonulin as a biomarker of gastrointestinal tract permeability for predicting hepatic encephalopathy after transjugular intrahepatic portosystemic shunt creation
ResearchCollaborator · Awarded by SIR Foundation · 2023 - 2025Pro00113953_KEZAR Study A Randomized, Double-blind, Placebo-controlled, Phase 2a Study with Open-label Extension to Evaluate the Safety and Efficacy of Zetomipzomib (KZR-616) in Patients with Autoimmune Hepatitis
Clinical TrialPrincipal Investigator · Awarded by Kezar Life Sciences, Inc. · 2023 - 2025Development of a multi-center research infrastructure for the Strength Training Intervention (STRIVE) for liver transplant candidates
Clinical TrialPrincipal Investigator · Awarded by University of California - San Francisco · 2018 - 2019External Relationships
- Mallinckrodt Pharmaceuticals
- Daniel Johnson Family
- Medical Education Resources
- Medical legal consulting
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.